This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The literature search was performed using PubMed, and covered articles published from 1990 through March 2005.
Criteria used to ensure the validity of primary studies
Two independent reviewers performed the literature search. Both reviewers critiqued each abstract, with individual papers pulled for further review if they met the criteria or if the methodology was unclear. For CT colonography, only studies using the segmental unblinding technique were included, whereas for colonoscopy, both segmental unblinding and back-to-back colonoscopy studies were used to assess diagnostic accuracy.
Methods used to judge relevance and validity, and for extracting data
Two external-content experts were consulted to ascertain that no other published or unpublished studies were overlooked.
Number of primary studies included
The authors reported that at least 35 primary studies were included in the review for different purposes (e.g. prevalence and incidence rates, sensitivity and specificity, adherence to screening and treatment).
Methods of combining primary studies
A narrative method was used to combine the studies. For the size-specific sensitivities and specificities and the risk of perforation, a weighted average was used for the base-case estimates. The prevalence of polyps and the proportion that were adenomatous within each size category were averaged from CT colonography studies, where available.
The probability of a polyp being adenomatous was 61% for 6-to 9-mm polyps and 67% for polyps >/= 10 mm.
The 3-year risk of cancer from a missed adenoma was 0.9 for 6-to 9-mm polyps and 1.5% for polyps >/= 10 mm.
The sensitivity of CT colonography was 61% for 6-to 9-mm polyps and 71% for polyps >/= 10 mm, whereas the sensitivity values for colonoscopy were 94% (6 -9 mm in size) and 96% (>/= 10 mm in size), respectively. The specificity, considering that a "true negative" was a patient with no polyps >/= 5 mm in size, was 84% for CT colonography and 100% for colonoscopy.
The risk of bleeding was 0.03% after diagnostic colonoscopy and 0.5% after polypectomy.
The risk of perforation was 0.09% after diagnostic colonoscopy and 0.24% after polypectomy.
The risk of death from perforation was 4.9%.
All cancers discovered after 3 years would have a 5-year survival of 90%.
Methods used to derive estimates of effectiveness
This analysis was based on published data and authors' assumptions.
Estimates of effectiveness and key assumptions
The authors considered clinically significant polyps to be those larger than 5 mm. When identified with CT colonography, they were assumed to lead to prompt referral for colonoscopy, and polypectomy if confirmed. The authors assumed that polyps 5 mm or less in size would not require further testing: their malignant potential is low, especially in the short term. In addition, the authors assumed a baseline prevalence of colorectal cancer of 0 and no difference in screening adherence at baseline.
Measure of benefits used in the economic analysis
The measures of benefits used were the deaths avoided from perforations, additional deaths from missed adenomas and life-years gained (LYG). The health benefits were discounted at a rate of 3% per year.
Direct costs
The direct health care costs of colonoscopy (including therapeutic use and treatment of bleeding and perforation) and CT colonography were tabulated for local estimations. They included detailed procedural costs for diagnostic and therapeutic colonoscopy (including physician and nursing charges), costs for medical and surgical supplies, medications and cleaning, and amortised costs for overheads. The costs of complications were taken from medical records, and only complications resulting from colonoscopy confirmed by chart review were included in the analysis.
Since CT colonography is not currently part of any provincial fee schedule in Canada, the cost of it was estimated using the Provincial Common Procedure List Catalogue to calculate the cost of diagnostic imaging tests. An additional cost was estimated to cover a radiologist's interpretation fee, support staff, supplies and equipment maintenance. It excluded capital expenditures and thus assumed that the extra CT scans could be done by means of existing capital infrastructure. Moreover, the CT cost did not include the anticipated higher radiologist's interpretation fee, given the extra time required to interpret a CT colonography study. The authors added an additional fee to account for the cost of extracolonic findings.
The lifetime cost of early-stage colorectal cancer was taken from the literature. Discounting was carried out at a rate of 3%. The quantities and the costs were not analysed separately. The estimations of the quantities and the costs were modelled. The price year was not reported. The costs were treated deterministically and no statistical tests were carried out.
Statistical analysis of costs

Indirect Costs
Productivity losses were estimated and reported, but they were not used in the base-case analysis, only in the sensitivity analysis. They were estimated using average hourly earnings from the Canadian Socioeconomic Information Management System. The authors estimated the indirect costs for patients and escorts for colonoscopy, and for patients for CT colonography. Discounting was carried out at a rate of 3%. The price year was not reported.
Currency
Canadian dollars (Can$).
Sensitivity analysis
To assess the robustness of their conclusions, the authors subjected each of the variables modelled to sensitivity analyses. Plausible ranges, taken from published literature, were used. In particular, the authors modelled a wide range of increased screening adherence for CT colonography over colonoscopy. Variations in the test performance of CT colonography, as reported in medical literature, were used for presenting best-and worst-case scenario analyses. The estimated risk of cancer from missed adenomas and the risk of colonoscopy-associated perforation and death were also tested.
Estimated benefits used in the economic analysis
The numbers of deaths per 100,000 people screened for colon cancer were as follows:
for the colonoscopy strategy, 6.03 perforation-related deaths, 0.64 cancer-related deaths from missed adenomas, and 6.67 total deaths; for the CT colonography strategy, 2.25 perforation-related deaths, 4.75 cancer-related deaths from missed adenomas, and 7.00 total deaths.
Cost results
The total costs were Can$61.5 million for the colonoscopy strategy and Can$63.8 million for the CT colonography strategy, both per 100,000 people screened for colon cancer.
Synthesis of costs and benefits
According to the base-case estimates, a strategy of CT colonography for colorectal cancer screening would cost Can$2.27 million more than colonoscopy per 100,000 patients screened, and would result in 0.33 extra deaths per 100,000 patients screened. As such, colonoscopy was both less expensive and more effective (i.e. dominant).
The results from the sensitivity analyses were sensitive to variations in the test performance of CT colonography. In the best-case scenario (sensitivity 94%, specificity 80%), the incremental cost of CT colonography was $220,000 per LYG.
In the worst-case scenario (sensitivity 55%, specificity 91%), the cost-savings of $4.51 million for CT colonography yielded an incremental cost of colonoscopy of $106,000 per LYG.
The results were also sensitive to the estimated risk of cancer from missed adenomas and the risk of colonoscopyassociated perforation and death. Colonoscopy was no longer dominant when the cancer risk of a missed adenoma 6 -9 mm in size was decreased to 0; CT colonography then had an incremental cost per LYG of Can$42,900. When the risk of perforation from colonoscopy was increased to 0.2%, CT colonography became an attractive alternative, with a cost per LYG of Can$2,130. Increasing the risk of death from colonoscopic perforation to 14% generated a cost per LYG of $18,200 for CT colonography. There would appear to be some discrepancies between the values reported in the table and in the text.
